Efficacy News and Research

RSS

Antibody cocktail could change the way the world fights influenza

An unusual therapy developed at The Jackson Laboratory (JAX) could change the way the world fights influenza, one of the deadliest infectious diseases.

11 Sep 2025

GABA identified as key blocker of neural repair in spinal cord injury

Spinal cord injuries caused by external trauma, such as traffic accidents or falls, often lead to the permanent loss of motor and sensory functions.

10 Sep 2025

Detecting causality in neural spike trains using a new technique

Understanding the brain's functional architecture is a fundamental challenge in neuroscience. The connections between neurons ultimately dictate how information is processed, transmitted, stored, and retrieved, thus forming the basis of our cognitive functions.

10 Sep 2025

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Discover how real-time Raman monitoring enhances API control and quality during hot melt extrusion.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 10 Sep 2025

Bee-sting inspired microneedle patches offer pain-free drug delivery

Neurological diseases affect millions worldwide, and the need for long-term patient-friendly treatments has never been greater.

10 Sep 2025

Bottlebrush particles deliver large range of chemotherapy drugs directly to tumor cells

Using tiny particles shaped like bottlebrushes, MIT chemists have found a way to deliver a large range of chemotherapy drugs directly to tumor cells.

10 Sep 2025

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

10 Sep 2025

Berberine improves cognitive function in diabetic encephalopathy mice

A recent study published in Engineering has shed new light on the potential therapeutic effects of berberine (BBR), a natural compound derived from traditional Chinese medicine, in treating diabetic encephalopathy (DE).

9 Sep 2025

Smart material delivers drugs in response to arthritis flare-ups

Researchers have developed a material that can sense tiny changes within the body, such as during an arthritis flare-up, and release drugs exactly where and when they are needed.

8 Sep 2025

Common diabetes drug metformin cuts long covid risk by 64 percent in UK study

A large UK-based retrospective cohort study found that initiating metformin within 90 days of COVID-19 diagnosis reduced the risk of Long COVID by 64% in overweight and obese adults. The findings suggest metformin may offer a low-cost preventive option pending confirmation from randomized trials.

8 Sep 2025

New strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights

People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.

8 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

8 Sep 2025

Can an allergy spray help prevent COVID-19?

Previous
1
...
53
54
55
56
57
58
59
...
1332
Next

Efficacy News and Research

Antibody cocktail could change the way the world fights influenza

GABA identified as key blocker of neural repair in spinal cord injury

Detecting causality in neural spike trains using a new technique

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Bee-sting inspired microneedle patches offer pain-free drug delivery

Bottlebrush particles deliver large range of chemotherapy drugs directly to tumor cells

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

Berberine improves cognitive function in diabetic encephalopathy mice

Smart material delivers drugs in response to arthritis flare-ups

Common diabetes drug metformin cuts long covid risk by 64 percent in UK study

New strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

New antibody-drug conjugate iza-bren may offer promising treatment option for EGFR-mutated NSCLC patients

Can an allergy spray help prevent COVID-19?

New drug candidate STF 1623 activates innate immunity in solid tumors

Oncolytic viruses integrated with immunotherapy for next-generation cancer treatment

Natural medicines as emerging tools to target the tumor vascular microenvironment

Blood-based biomarkers reveal barriers to diversity in Alzheimer’s disease trials

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News